JP2022548902A5 - - Google Patents

Info

Publication number
JP2022548902A5
JP2022548902A5 JP2022517339A JP2022517339A JP2022548902A5 JP 2022548902 A5 JP2022548902 A5 JP 2022548902A5 JP 2022517339 A JP2022517339 A JP 2022517339A JP 2022517339 A JP2022517339 A JP 2022517339A JP 2022548902 A5 JP2022548902 A5 JP 2022548902A5
Authority
JP
Japan
Prior art keywords
seq
cells
expression construct
scfv
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548902A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050864 external-priority patent/WO2021055349A1/en
Publication of JP2022548902A publication Critical patent/JP2022548902A/ja
Publication of JP2022548902A5 publication Critical patent/JP2022548902A5/ja
Pending legal-status Critical Current

Links

JP2022517339A 2019-09-18 2020-09-15 Bcma陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法 Pending JP2022548902A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902237P 2019-09-18 2019-09-18
US62/902,237 2019-09-18
PCT/US2020/050864 WO2021055349A1 (en) 2019-09-18 2020-09-15 A method of engineering natural killer-cells to target bcma-positive tumors

Publications (2)

Publication Number Publication Date
JP2022548902A JP2022548902A (ja) 2022-11-22
JP2022548902A5 true JP2022548902A5 (cg-RX-API-DMAC7.html) 2023-09-29

Family

ID=74883668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517339A Pending JP2022548902A (ja) 2019-09-18 2020-09-15 Bcma陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法

Country Status (7)

Country Link
US (1) US20220370500A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022548902A (cg-RX-API-DMAC7.html)
CN (1) CN114729046A (cg-RX-API-DMAC7.html)
AR (1) AR119990A1 (cg-RX-API-DMAC7.html)
TW (1) TW202124447A (cg-RX-API-DMAC7.html)
WO (1) WO2021055349A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
JP7773789B2 (ja) 2020-03-28 2025-11-20 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 癌の治療のための細胞免疫療法
AU2022273049A1 (en) * 2021-05-14 2024-01-04 Board Of Regents, The University Of Texas System Chimeric polypeptides and methods of use
CA3233096A1 (en) * 2021-10-20 2023-04-17 Board Of Regents, The University Of Texas System Engineering nk cells with a car construct with optimal signaling
AU2022372894A1 (en) 2021-10-20 2024-04-18 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023177954A1 (en) * 2022-03-18 2023-09-21 University Of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof
JP2026512487A (ja) * 2023-04-18 2026-04-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Bcmaキメラ抗原受容体及びその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013246443B2 (en) * 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
TWI700298B (zh) * 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
JP2020517259A (ja) * 2017-04-19 2020-06-18 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
US11905528B2 (en) * 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
CN109468283A (zh) * 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN109734814A (zh) * 2019-02-12 2019-05-10 南京卡提医学科技有限公司 具有免疫受体的工程化t细胞治疗癌症的用途

Similar Documents

Publication Publication Date Title
JP2022184852A5 (cg-RX-API-DMAC7.html)
JP2023509766A5 (cg-RX-API-DMAC7.html)
AU2016342560B2 (en) Receptor
JP2022550899A5 (cg-RX-API-DMAC7.html)
Colucci et al. What does it take to make a natural killer?
JP6990244B2 (ja) ヒトcd123を標的とするキメラ受容体リガンド及びその応用
JP2022548943A5 (cg-RX-API-DMAC7.html)
JP2024519515A5 (cg-RX-API-DMAC7.html)
JP2022542321A5 (cg-RX-API-DMAC7.html)
CN109280086B (zh) 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体
JP2021505131A5 (cg-RX-API-DMAC7.html)
JP2024513906A5 (cg-RX-API-DMAC7.html)
JP2018504144A (ja) Cll1特異的多鎖キメラ抗原受容体
AU2018321134B2 (en) Chimeric antigen receptor and CAR-T cells that bind CXCR5
JP2024525492A5 (cg-RX-API-DMAC7.html)
JP2024525609A5 (cg-RX-API-DMAC7.html)
JP2023548467A5 (cg-RX-API-DMAC7.html)
JP2024521185A5 (cg-RX-API-DMAC7.html)
JP2024521566A5 (cg-RX-API-DMAC7.html)
JP2024527879A5 (cg-RX-API-DMAC7.html)
WO2023193660A1 (zh) 增强型嵌合抗原受体及其应用
JP2023540551A (ja) 免疫療法組成物
JP2024504164A5 (cg-RX-API-DMAC7.html)
KR20210111244A (ko) 태반-유래 동종이계 car-t 세포 및 이의 용도
CN110438082A (zh) 表达il-21r结合蛋白的免疫效应细胞